ArticleClinical case reports2026
Hemoperfusion as Adjunctive Therapy in Severe Snake Envenomation Refractory to Antivenom: A Case Series.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Snake envenomation remains a significant cause of morbidity worldwide, with antivenom serving as the cornerstone of treatment. This case series describes outcomes of three male patients (ages 34-63 years) with severe envenomation who demonstrated progressive local swelling and coagulopathy despite receiving at least 15 vials of antivenom. All received adjunctive hemoperfusion using a Nipro HA230 cartridge via femoral venous access (six two-hour sessions over three days). All patients survived and were discharged after 4-5 days with normalized coagulation parameters and resolved swelling. No hemoperfusion-related complications were documented. Total antivenom ranged from 15 to 25 vials. These findings suggest hemoperfusion may be a feasible adjunctive therapy in refractory cases, though the observational design precludes definitive conclusions. Hemoperfusion should be considered experimental, reserved for severe refractory cases in well-resourced settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.